Mountain View biotech’s lead GPX4 modulator, RLS-1496, has delivered positive preliminary Phase 1 results in first human trial of a GPX4 modulator.
When the founders of Rubedo Life Sciences chose their company name – rubedo being the final, golden stage of the alchemical process – they were making a statement. The transformation of base matter into something precious is, after all, a fitting metaphor for what the company is attempting: converting the science of cellular senescence into genuine medicines that could redefine how we treat the diseases of aging.
Founded in 2018 and headquartered in Mountain View, California, Rubedo has spent the better part of seven years building something that most longevity biotechs only talk about: a platform-driven, AI-powered drug discovery engine that has now delivered a first-in-class clinical asset. With 34 employees and venture capital backing, the company punches well above its weight – and the longevity field is starting to take notice.
The ALEMBIC engine: where AI meets aging biology
At the heart of Rubedo’s strategy is ALEMBIC, a proprietary AI-driven drug discovery platform that is, in many ways, the company’s most valuable asset. The name is no accident – an alembic is the vessel used in classical alchemy to distil and purify substances, and that is precisely what the platform does: it distils biological complexity into actionable drug targets.
ALEMBIC integrates machine learning with single-cell RNA sequencing (scRNAseq), spatial omics and other multi-omics data to identify disease-specific senescent cell populations and their unique molecular vulnerabilities. Crucially, the platform is therapeutic-area agnostic – the same discovery methodology can be applied across dermatology, pulmonology, oncology, neurology, and metabolic disease. This is not a one-trick pony.
The platform’s translational credentials are already impressive. In 2025, research powered by ALEMBIC led to a landmark publication in Nature Neuroscience identifying senescent neurons as drivers of neuropathic pain – a finding that opens an entirely new therapeutic frontier. More immediately, ALEMBIC generated RLS-1496, which has now become the first GPX4-modulating senolytic to enter human clinical trials anywhere in the world.
RLS-1496: a new mechanism for an old problem
The senolytic field has long been dominated by repurposed compounds – dasatinib, quercetin, navitoclax – that were never designed with precision senescent cell targeting in mind. Rubedo has taken a fundamentally different approach.
RLS-1496 is a selective small-molecule modulator of GPX4 (glutathione peroxidase 4), the critical antioxidant enzyme that protects cells from lipid peroxidation-induced ferroptotic cell death. Here is the elegant biology: senescent cells, due to their altered metabolic and antioxidant profiles, are inherently more ferroptosis-sensitive than healthy cells. They upregulate GPX4 as a compensatory survival mechanism – which paradoxically makes them selectively vulnerable to GPX4 modulation.
This dual-action capacity – driving ferroptotic death in pathological, so-called ‘zombie’ cells while actively helping stressed, non-senescent cells restore redox balance, functional homeostasis and tissue health – is why Rubedo is reclassifying RLS-1496 not simply as a senolytic, but as a ‘SenoAdaptive’ drug. It is the first in a new class of Adaptive Senotherapeutics designed to modulate GPX4 for a state-dependent response, suggesting a broader regenerative and disease-modifying potential than previously possible.
The result is a disease-modifying senolytic that addresses the root cause of chronic, age-related pathology: the accumulation of senescent cells that secrete pro-inflammatory cytokines (the so-called SASP – senescence-associated secretory phenotype) and drive tissue dysfunction across multiple organ systems.
A clinical program gathering momentum
The pace of RLS-1496’s clinical development has been striking. The company has now opened two parallel clinical tracks:
Track 1 – European Phase 1 (topical, dermatology): In May 2025, Rubedo announced that the first patient had been dosed in a Phase 1 basket trial at a single center in the Netherlands. The study is evaluating topical RLS-1496 in adults with mild-to-moderate stable plaque psoriasis, while simultaneously assessing biomarkers of skin aging and biological clock reversal in photoaged skin. The trial is designed to expand to additional inflammatory skin conditions including atopic dermatitis, vitiligo, rosacea, alopecia areata and scleroderma – a broad senolytic canvas. A second Phase 1b trial is ongoing in atopic dermatitis and skin aging, also in the Netherlands.
Track 2 – US Phase 1b/2a (actinic keratosis): In September 2025, the FDA cleared an IND for a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK) – a pre-cancerous skin age-related condition characterised by high senescent cell burden and elevated p16INK4a expression. The trial (NCT07340697) began enrolling in January 2026. The rationale is compelling: AK lesions are essentially a localised senescence problem, and RLS-1496’s ability to selectively clear senescent cells via ferroptosis could address the underlying cellular aging pathology rather than simply managing symptoms.
The competitive landscape for AK is currently dominated by tirbanibulin (Klisyri), 5-fluorouracil, diclofenac and imiquimod – all of which work through broad antiproliferative or immunomodulatory mechanisms. RLS-1496 is the first GPX4-selective modulator to enter clinical development for any dermatological indication and the first senolytic to specifically target the ferroptosis pathway in AK.
Clinical proof of concept (Track 1)
In March 2026, Rubedo reported positive preliminary results from its Phase 1 trial in the Netherlands, marking a historic first for the senolytic field. The study successfully met its primary endpoint of safety and tolerability, but the most significant takeaway was the early “clinical signal” observed in just four weeks. Psoriasis patients experienced an average 20% reduction in epidermal thickness, while 25% of atopic dermatitis patients reported a clinically meaningful reduction in itching. Biopsies confirmed the drug’s mechanism, showing dose-dependent target engagement and a clear reduction in “zombie” cell markers and inflammatory cytokines like IL-19.
Reversing the clock (photoaging & Track 2)
The data also showed results in the treatment of photoaged skin. Spatial transcriptomics and proteomics revealed that RLS-1496 treatment led to increased collagen gene and protein expression in dermal fibroblasts, effectively reversing molecular markers of skin aging. With this proof-of-concept secured, attention now turns to Track 2, the ongoing US-based Phase 1b/2a study in actinic keratosis (NCT07340697). Rubedo expects to complete this study later in 2026, creating a comprehensive dataset of approximately 70 subjects that could bridge the gap between treating specific skin diseases and addressing the root causes of systemic biological aging.
Beyond dermatology, the systemic formulation of RLS-1496 is targeting a broader set of age-related indications – including idiopathic pulmonary fibrosis, NASH, sarcopenia, systemic sclerosis and metabolic syndromes – with Phase 1 entry planned for 2027. The senolytic therapeutics market, currently valued at approximately $4.5 billion, is projected to reach $8.72 billion by 2030, and Rubedo is positioning itself as a leader in that space.
Beyond RLS-1496: a pipeline built for scale
While RLS-1496 commands the headlines, Rubedo’s broader pipeline based on different targets and therapeutic modalities reflects the platform’s ambition:
- RBO-2XX (Respiratory): In IND-enabling preclinical studies, targeting respiratory diseases – a natural extension of the company’s earlier CIRM-funded work on idiopathic pulmonary fibrosis.
- RBO-3XX (Metabolic): In discovery stage, targeting metabolic and endocrine diseases – an area where senescent cell accumulation is increasingly recognised as a driver of insulin resistance and metabolic dysfunction.
- RBO-4XX (Neuro): Also in discovery, targeting neurodegenerative diseases – a programme that gains scientific credibility from the company’s 2025 Nature Neuroscience publication on senescent neurons in neuropathic pain.
Each of these programmes is being generated by the same ALEMBIC platform, meaning that the scientific and chemical learnings from RLS-1496 can be systematically applied across therapeutic areas focusing on different cell types and therapeutic novel targets.
Strategic partnerships: Beiersdorf bets on senescence
In April 2024, Rubedo announced a multi-year strategic partnership with Beiersdorf AG – the global skincare giant behind NIVEA and Eucerin – to develop a breakthrough anti-aging solution for the global face care market. Beiersdorf’s corporate venture arm, Oscar & Paul, also made a direct investment in Rubedo as part of the deal.
The collaboration is exploring novel ALEMBIC-derived compounds with senolytic and anti-inflammatory properties for topical facial care – a move that bridges the gap between clinical therapeutics and the rapidly growing longevity skincare market. It is a smart strategic play: Rubedo gains commercial validation and non-dilutive resources, while Beiersdorf gains access to cutting-edge senescence biology that no cosmetics company could generate in-house.
The team: deep expertise, broad ambition
Rubedo’s leadership team is another asset. Frederick Beddingfield III, MD, PhD, the CEO, brings 22 years of biopharmaceutical experience including senior roles at Allergan – precisely the kind of dermatology and regulatory expertise needed to navigate RLS-1496 through the clinic. Marco Quarta, PhD, Cofounder and CSO, is a Stanford-trained neuroscientist with deep roots in aging biology and cellular senescence. Mark Gallop, PhD, Co-Founder and Chairman, is a veteran medicinal chemist and serial entrepreneur with world-class expertise in prodrug and other selective chemistry strategies – the very chemistry that underpins Rubedo’s selective senolytic approach. The team is rounded out by a Chief Medical Officer (Mary Spellman, MD), a Chief Business Officer (Ali Siam, MBA), and a Senior VP of Drug Discovery (Ofir Moreno, PhD) – a full commercial and scientific bench that is unusual for a company of just 34 people.
Funding and IP: building the moat
Rubedo is venture capital-backed and privately held. In February 2023, the company received $1.45 million in non-dilutive funding from the California Institute for Regenerative Medicine (CIRM) to support its idiopathic pulmonary fibrosis programme – a grant that served as an important external validation of the platform’s scientific credibility.
On the intellectual property front, the company has been actively filing patents, with at least 10 pending patent applications filed between late 2024 and mid-2025 – a filing cadence that reflects the pace of platform-driven discovery and the company’s intent to build durable competitive barriers around its GPX4 modulation chemistry and senolytic prodrug strategies.
The bigger picture: why Rubedo matters
The senolytic field has had a complicated few years. Unity Biotechnology’s early stumbles with UBX0101 in osteoarthritis dampened enthusiasm, and the repurposed compound approach (dasatinib + quercetin) has shown only modest clinical signals. The field needed a genuinely novel mechanism – one designed from the ground up for selectivity and translational rigor.
With the March 2026 data, RLS-1496 has emerged as that mechanism. By exploiting the intrinsic ferroptosis sensitivity of senescent cells through GPX4 modulation, Rubedo has not only identified a biological vulnerability but has now delivered the first-ever human clinical proof-of-concept for a precision senolytic. The 20% reduction in skin thickness and the molecular reversal of aging markers in photoaged skin provide the “golden” validation the company’s name promised.
But the real prize – and the reason the longevity community is watching closely – is what comes next. The success of this topical application paves the way for a systemic selective GPX4 modulator that can clear specific types of pathological senescent cells from the lung, liver, muscle, and brain. This would represent a genuine step-change in geroscience therapeutics.
The alchemical transformation is no longer a theory; it is underway in the clinic. The question is no longer whether senescent cells can be targeted with precision – it is how quickly Rubedo can scale this success across the diseases of aging.
READ MORE: Rubedo reports early clinical signal for senotherapeutic drug
